Restoring Balance: Current and Emerging Management of MGD (CE Webcast)
Activity Description and Purpose
Meibomian gland dysfunction is characterized by inflammation in the meibomian glands in the eyelids, which leads to poor tear film quality and exacerbated evaporation of the tear film from the ocular surface. Meibomian gland dysfunction is a major driver of dry eye disease, yet diagnosis is often delayed, leading to delayed treatment and undesirable patient outcomes. In this educational activity, experts will present real-world cases that review best practices in the early diagnosis of meibomian gland dysfunction, review current treatment strategies, and discuss emerging treatments for meibomian gland dysfunction.
This educational activity is intended for optometrists.
After completing this activity, participants will be better able to:
- Describe the prevalence of meibomian gland dysfunction
- Incorporate routine meibomian gland expression into practice
- Describe the pathophysiology of meibomian gland dysfunction–associated dry eye disease
- Design evidence-based treatment plans for persons with meibomian gland dysfunction–associated dry eye disease
- Evaluate clinical trial data for agents under development for the treatment of meibomian gland dysfunction–associated dry eye disease
|Kelly K. Nichols, OD, MPH, PhD, FAAO (Chair)|
University of Alabama at Birmingham School of Optometry
|Paul Karpecki, OD, FAAO|
University of Pikeville School of Optometry
Director, Cornea and External Disease
Kentucky Eye Institute
|Leslie E. O'Dell, OD, FAAO|
Medical Director and Director of Clinical Research
Medical Optometry America
|Walter O. Whitley, OD, MBA, FAAO|
Director, Optometric Services
Virginia Eye Consultants
Virginia Beach, Virginia
The content of this COPE-accredited CE activity was planned and prepared independently by MedEdicus without input from members of an ineligible company. All relevant relationships with ineligible companies have been mitigated.
Paul Karpecki, OD, is a consultant for AbbVie Inc, Akorn, Inc, Alcon, Aldeyra Therapeutics, Allergan, Ametek, Inc, Atlas Medical GmbH, Avellino, Azura Ophthalmics Ltd, Bausch & Lomb Incorporated, Bio-Tissue, BlephEx, Bruno Vision, Cambium Medical Technologies, Dompé US, Inc, Gobiquity, Haag-Streit Group, Hilco Vision, Icare USA Inc, Imprimis Pharmaceuticals, Inc, Kala Pharmaceuticals, Kiora Pharmaceuticals, Inc, Konan Medical USA, Inc, Lentechs, Neurolens, Novartis Pharmaceuticals Corporation, OASIS Medical, OCULUS, Inc, OCuSOFT Inc, Optase, Oyster Point Pharma, Inc, Rendia, Inc, RVL Pharmaceuticals, Inc, RxSIGHT, ScienceBased Health, Sentiss Pharma Pvt Ltd, Sight Sciences, StepWise Medical, LLC, Sun Pharmaceutical Industries, Inc, Surface Pharmaceuticals Inc, Tarsus Pharmaceuticals, Inc, Thea Pharmaceuticals Limited, Visant Medical, Inc, Vital Tears LLC, and Zeiss; is on the speakers bureau for Aerie Pharmaceuticals, Inc, Johnson & Johnson Vision Care, Inc, and Mallinckrodt; is on the advisory board of AstaReal, Inc; and has individual stocks or stock options in SilkTech Biopharmaceuticals.
Kelly K. Nichols, OD, MPH, PhD, is a consultant for AbbVie Inc, Aerie Pharmaceuticals, Inc, Aldeyra Therapeutics, Allergan, Axim Biotech, Bausch & Lomb Incorporated, Bruder Healthcare*, Dompé US, Inc, Hanall Biopharma, Kala Pharmaceuticals, Novartis Pharmaceuticals Corporation, Osmotica Pharmaceuticals plc, Oyster Point Pharma, Inc, RVL Pharmaceuticals, Inc, ScienceBased Health*, Sight Sciences, SilkTech Biopharmaceuticals*, Sun Pharmaceutical Industries, Inc*, Tarsus Pharmaceuticals, Inc, Thea Pharmaceuticals Limited, TopiVert Ltd*, Visionology, Yuyu Pharma, Inc; is a contracted researcher for Allergan*, Kala Pharmaceuticals*, and TearScience; and has individual stocks or stock options in Axim Biotech, Tear Film Innovations*, and Visionology.
Leslie E. O’Dell, OD, is a consultant for Alcon, Allergan, Bausch & Lomb Incorporated, Eye Eco Inc, Eyedetec Medical, Inc, Novartis Pharmaceuticals Corporation, Ocuphire Pharma, Oyster Point Pharma, Inc, Sun Pharmaceutical Industries, Inc, and Tarsus Pharmaceuticals, Inc; is on the speakers bureau for Aerie Pharmaceuticals, Inc, Allergan, Oyster Point Pharma, Inc, and Sun Pharmaceutical Industries, Inc; and has individual stocks or stock options in Eyedetec Medical, Inc.
Walter O. Whitley, OD, MBA, is a consultant for Alcon, Allergan, Bausch & Lomb Incorporated, Bruder Healthcare, Dompé US, Inc, Kala Pharmaceuticals, Novartis Pharmaceuticals Corporation, Oyster Point Pharma, Inc, Santen Inc, ScienceBased Health, and Sun Pharmaceutical Industries, Inc; and is on the speakers bureau for Alcon, Allergan, Bausch & Lomb Incorporated, Kala Pharmaceuticals, Oyster Point Pharma, Inc, Santen Inc, and Sun Pharmaceutical Industries, Inc.
* The financial relationship existed during the last 24 months but has now ended
Planners, Managers, and Writers
Carrie Allen, PharmD, BCPP, BCPS, MedEdicus Content Manager for this activity, was previously employed by CVS within the past 2 years, but that relationship has ended.
Other MedEdicus planners, managers, and writers have no relevant commercial relationships to disclose.
COPE approved for 2.0 CE credits for optometrists.
COPE Course ID: 81993-TD (Asynchronous)
COPE Course Category: Treatment & Management of Ocular Disease
Disclosure of Commercial Support
This continuing education activity is supported through an educational grant from Bausch & Lomb Incorporated.
This educational activity may include discussion of unlabeled and/or investigational uses of drugs and devices. Please refer to the official prescribing information for each drug or device discussed in this activity for approved dosing, indications, and warnings.
For questions about this educational activity, please contact MedEdicus LLC at email@example.com.
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of MedEdicus LLC or Bausch & Lomb Incorporated.
©2023 MedEdicus LLC. 278.2
- 2.00 COPE